Cellectis (NASDAQ:CLLS) Announces Quarterly Earnings Results

by · The Cerbat Gem

Cellectis (NASDAQ:CLLS – Get Free Report) issued its quarterly earnings data on Monday. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.26) by $0.08, Zacks reports. Cellectis had a negative net margin of 84.92% and a negative return on equity of 69.38%.

Cellectis Price Performance

Shares of NASDAQ CLLS traded up $0.13 during midday trading on Monday, hitting $3.98. The company had a trading volume of 29,003 shares, compared to its average volume of 41,561. The company has a quick ratio of 1.62, a current ratio of 1.62 and a debt-to-equity ratio of 0.98. Cellectis has a twelve month low of $1.33 and a twelve month high of $5.48. The business has a 50-day simple moving average of $3.68 and a two-hundred day simple moving average of $4.00. The firm has a market capitalization of $399.35 million, a price-to-earnings ratio of -5.94 and a beta of 2.94.

Hedge Funds Weigh In On Cellectis

Several hedge funds have recently added to or reduced their stakes in the business. Global Retirement Partners LLC purchased a new position in Cellectis during the 4th quarter valued at about $34,000. Millennium Management LLC increased its holdings in Cellectis by 61.9% during the 3rd quarter. Millennium Management LLC now owns 57,740 shares of the biotechnology company’s stock valued at $165,000 after acquiring an additional 22,080 shares in the last quarter. Virtu Financial LLC purchased a new position in Cellectis during the 3rd quarter valued at about $72,000. Acadian Asset Management LLC increased its holdings in Cellectis by 132.9% during the 1st quarter. Acadian Asset Management LLC now owns 46,377 shares of the biotechnology company’s stock valued at $55,000 after acquiring an additional 26,461 shares in the last quarter. Finally, Marshall Wace LLP increased its holdings in Cellectis by 1,610.3% during the 4th quarter. Marshall Wace LLP now owns 178,473 shares of the biotechnology company’s stock valued at $864,000 after acquiring an additional 168,038 shares in the last quarter. 63.90% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

CLLS has been the topic of several research reports. Citizens Jmp reissued a “market outperform” rating and set a $8.00 price objective on shares of Cellectis in a research report on Tuesday, April 14th. Jefferies Financial Group started coverage on shares of Cellectis in a research report on Tuesday, February 17th. They set a “buy” rating and a $7.00 price objective on the stock. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Cellectis in a research note on Monday, April 20th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $6.75.

Read Our Latest Research Report on CLLS

About Cellectis

(Get Free Report)

Cellectis is a clinical‐stage biopharmaceutical company specializing in the development of gene‐edited cell therapies for oncology. Founded in 1999 and headquartered in Paris, France, the company also maintains operations in New York City and Raleigh, North Carolina. Cellectis applies its proprietary TALEN genome editing platform to engineer allogeneic chimeric antigen receptor T‐cell (CAR‐T) candidates designed to target blood cancers and solid tumors.

The company’s core business activities encompass the discovery, development and manufacturing of off‐the‐shelf immunotherapies.

Read More